Dr. Michael Johnson is a 2017 and 2019 Forbes 30 Under 30 honoree and the CEO and Co-Founder of Visikol Inc., which is a bio-imaging company that spun out of Rutgers University in 2016 and that Michael founded along with his fellow PhD candidate Thomas Villani and colleague Nick Crider. Michael has a diverse background with experiences in both the technical and business considerations of running a biotech business.
Brian Jones & Andres Tellez
Brian Jones has more than 25 years of drug discovery experience and has led the molecular discovery behind more than 20 INDs across several therapeutic areas. Most recently he spent 11 years at Novartis, where he was head of discovery chemistry for NIBR in Cambridge, Mass. Prior to that, Brian was at Merck for 16 years, initially as director of medicinal chemistry in Rahway, N.J. and subsequently as senior director at the Neuroscience Research Centre in the UK. Brian holds a Ph.D. in chemistry from Imperial College, London. He was a NATO post-doctoral fellow at Yale University.
Andres Tellez comes to Cedilla from Syros Pharmaceuticals, where he served as senior director of business development and helped secure the company’s partnerships with Incyte and Johnson and Johnson. Before joining Syros, Andres worked for several years at Cerulean Pharma, rising to director and acting head of business development. At Cerulean he served in a broad role, advancing strategic collaborations and supporting the company’s clinical development and fundraising efforts. Andres has a Ph.D. in biomedical informatics from Stanford University and an SB and M.Eng in EECS from MIT.
Keith Dionne is the founding CEO of Casma Therapeutics – a biotech company focused on developing drugs that enhance autophagy – a cell’s ability to breakdown and recycle protein aggregates – to treat serious diseases including neurodegeneration.
Keith is an industry veteran with 20+ years of experience leading U.S. and international biotechnology companies including Constellation Pharmaceuticals, Surface Logix, and Alantos Pharmaceuticals. He received his Ph.D. from MIT, is the father of 4 children and is an avid biker and soccer player.
Fiona is a bioinformatics scientist turned entrepreneur. Having worked at Illumina developing tools for interpretation of next-generation sequencing data and analyzing cancer genomes, she realized the main bottleneck for genome interpretation and precision medicine is accessing the right data, and so decided to disrupt outdated practices with the aim of accelerating drug discovery.
In 2013 Fiona founded DNAdigest as a charity, to promote best practices for efficient and ethical data sharing and, in 2014, she co-founded Repositive to develop an online community platform and global exchange for genomic data.
Fiona’s familiarity with the industry ensured that Repositive’s products – two to date, the Discover and Cancer Models platforms – would provide data access solutions while also respecting the industry need for privacy, data governance and IP protection, and this awareness was fundamental in securing £3M+ investment and support from early partners including AstraZeneca, Boehringer Ingelheim, XenTech and Shanghai LIDE Biotech.
Eric Banks is a computational biologist, institute scientist, and senior director of the Data Sciences Platform at the Broad Institute. He leads an amazing team of computational biologists and software engineers that implements novel computational methods, engineers, and operates large-scale production pipelines, and develops innovative infrastructure to handle the Broad Institute’s growing computational needs. He has led the development of the Genome Analysis Toolkit (GATK), creating analysis tools that are the standard-setters for variation discovery and data processing for next-generation sequencing projects.
Before joining the Broad in March 2009, Banks earned both a bachelor’s degree and Master of Engineering from MIT and a Ph.D. in computational biology from Princeton University.
Dr. Stephanie Hennek is an R&D Team Leader at Ultivue. As one of Ultivue's first employees, Stephanie led the establishment and implementation of Ultivue's InSituPlex technology for highly multiplexed tissue imaging. As an expert in bioanalytical chemistry, she serves as the technical lead for product development of UltiMapper kits and principal investigator on expanding technology application areas for Ultivue. Stephanie received her bachelor's degree from St. Lawrence University and obtained a PhD in Chemistry from Northwestern University where she studied molecular interactions at interfaces. Prior to joining Ultivue, Stephanie completed a postdoctoral fellowship with David Walt at Tufts University where she worked on single molecule assay development for single cell analysis and breast cancer diagnostics.
Nelia is the Global Lead for Digital Health consulting at IQVIA. She is passionate about bringing the best-tailored treatment, at the right time to patients and facilitating the connection to treatment with the right digital technologies. Throughout her career, Nelia has developed expertise across a wide range of products while working at the intersection of R&D and commercial, especially in digital health, tailored therapeutics, and clinical trial operations.
Before IQVIA, Nelia co-led the Personalized Medicine offering at Strategy&, (formerly Booz & Company). Prior to Strategy&, Nelia spent over seven years working in regulatory affairs for biopharmaceutical firms in the US, Canada, and Europe including Serono and Cell Therapeutics.
Nelia holds a degree in biology from Harvard University and an MBA from the Yale School of Management.
As Vice President of Data Management at Geisinger, Bipin ensures the development and maintenance of the enterprise data platforms, including the big data platform for the healthcare system. With over 20+ years of software management and digital innovation experience, Bipin is an energetic, senior-level technology executive with the ability to lead and motivate a team to high performance. Bipin holds expertise in growing and building technology teams, defining technology vision, strategic planning, managing application development and flawless application launch. In addition, Bipin holds expertise in onshore-offshore and multi- location development and is experienced in full cycle SDLC, both - Agile and traditional waterfall. Bipin is a proven expert in interpreting and applying cutting-edge technologies in building enterprise scale solutions.
Tariq Kassum, M.D. is Chief Operating Officer and Head of Corporate Development at Obsidian Therapeutics and was a member of the company’s founding team. Previously he was Vice President, Business Development and Strategy, for Takeda Oncology, with responsibility for transactions, collaborations, alliance management, and strategic planning. Before that, he led Takeda’s global corporate development efforts where he managed multiple acquisitions and divestitures. He began his career as an investment banker with CIBC World Markets serving clients in the biotechnology and specialty pharmaceuticals industries. He holds an M.D. from the University of Toronto and an A.B. from Cornell University, where he was named Degree Marshall of his graduating class.
Christopher Ahlberg is a Swedish-born technology entrepreneur and computer scientist. He is the CEO and co-founder of Recorded Future. Ahlberg is also an independent director of Hult International Business School.
Before co-founding Recorded Future, Ahlberg was the president of the Spotfire Division of Tibco, which he founded as an independent company in 1996. In 2007, Spotfire was acquired by Tibco for US$195 million in cash. Spotfire was founded based on his research on information visualization at the University of Maryland under the guidance of Ben Shneiderman. Ahlberg earned his doctorate from Chalmers University of Technology and has worked as a visiting researcher at the University of Maryland.
Robert G. Urban served as Johnson and Johnson’s Global Head of Johnson & Johnson Innovation, LLC. – a distinct business unit of J&J that serves as the Company’s enterprise-level externally facing R&D investment platform. Under his leadership, the J&J Innovation brand and global platform was launched and became the #1 recognized cross-sector (pharm, med device and consumer) innovation leader with a portfolio encompassing over 400 individual investments, including a globally distributed suite of incubators (JLABS) hosting over 300 start-ups and collectively generating a risk adjust enterprise value of over $5B.
Prior to joining J&J, Robert was the founding Executive Director of the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology (MIT); He was previously the CEO of Acretia Inc., a privately held intellectual property arbitrage organization and has served on the Board of many companies and organizations.
Josh is Founding Partner of First Round Capital, one of the leading seed-stage venture funds in the country. Josh has consistently ranked in the top 20 of Forbes annual “Midas List” of the top 100 tech investors.
Before becoming a venture capitalist, Josh founded three companies. In 1992 Josh co-founded Infonautics Corporation – taking it public in 1996. Josh founded Half.com in 1999 and led the company through its acquisition by eBay. And in 2003 Josh helped to found TurnTide, an anti-spam company that was acquired by Symantec.
Josh is an inventor on 13 U.S. Patents for his work in Internet technology.
Travis McCready is the President & CEO of the Massachusetts Life Sciences Center (MLSC), public-private investment fund with the mission of advancing the Massachusetts life sciences sector. The MLSC invests in scientific advancement, academic and workforce development, and new business opportunities that enrich the economy and advance patient health.
Mr. McCready has previously held leadership positions at The Boston Foundation, the Kendall Square Association, the Massachusetts Convention Center Authority, and Harvard University. A corporate lawyer, Mr. McCready received his B.A. from Yale University and J.D. from the University of Iowa.
Kevin joined Quanterix in 2014 and serves as the Chief Executive Officer and Executive Chairman. While at Quanterix, Kevin has led the Company to achieve significant success and growth, recently securing $55 million in funding that elevated the Company’s valuation to ten times its revenue. With over 25 years of experience in the life sciences space, he has dedicated his career to advancing the science of precision health and has a proven track record of commercializing disruptive technologies.
Kevin is also the founder of the Powering Precision Health Summit, the nation’s first summit dedicated to bringing the world’s leading physicians and scientists together to unveil their latest research on new biomarkers that are revolutionizing precision health.
Derek has 28 yrs experience in the Pharma industry, both Scientific and Informatics disciplines, (from bench science, to traditional IT to innovative IT). He specialises in informatics solutions for discovery Pharmacology (large and small molecule), with global strategic informatics oversight for solutions that support research.
Derek has a passion for the use and utility of "BigData " in research & academic collaborations in the pursuit of scientific insight, extending to involvement in a number of European Commission IMI, most heavily in OpenPHACTS (last 7 years), includes being a board member of the not-for-profit foundation since it was established. He is keen on the exploitation of semantic technologies to extract further scientific insight out of already existent data. I continue to work to make freely available public research data already semantically mapped and connected.
Derek also has a long-standing passion and focus with Neuroscience, to leverage IT innovations in the advancement of medicine discovery in video and signal processing along with machine learning & data acquisition solutions & implementations.
John Lunger is Senior Vice President, Manufacturing and Supply Chain at Adaptimmune, having joined the company in March of 2017. John is responsible for clinical manufacturing and global supply of Adaptimmune’s autologous T-cell therapy products. From 2015 through 2016 John was Head of Supply Chain and Commercial Product Supply at Merrimack Pharmaceuticals where he led clinical and commercial supply chain as well as the cross functional supply team for Onivyde, Merrimack’s first commercial product launched in October of 2015. Earlier in his career, he held various senior manufacturing, operational, and strategy roles with VWR International, Pfizer, and Wyeth Pharmaceuticals. In his nearly 10 years with Wyeth he had a number of leadership positions, including operations and supply chain strategy, supply management, procurement and strategic sourcing, business systems implementation, generic pharmaceutical business management, marketing, and site operations management in a pharmaceutical manufacturing plant in Ireland. John began his career serving as a nuclear trained officer on a U.S. Navy submarine, strategic supply chain consulting with Accenture, and business development with a start-up procurement services company. John holds a Bachelor of Science degree (with distinction) in Ocean Engineering from the U.S. Naval Academy and an MBA in economics and operations management from the University of Chicago’s Booth School of Business.
Dr. Mark Dudley is a Senior Vice President at Adaptimmune Therapeutics, a leader in genetically modified T cell therapies for solid cancers, where he is responsible for the development of manufacturing science and technology. Dr. Dudley has been a pioneer in the field of immunotherapy manufacturing, and has developed and implemented innovative early process design with accompanying analytics for multiple therapies. Previously, as Director of New Cell Products in the Cell and Gene Therapies division of Novartis Pharmaceutical Corp, Dr Dudley was responsible for establishing scalable, GMP-compliant production strategies and facilitating globalization of CAR-T products and platforms. As Director of the Cell Manufacturing Facility at the Surgery Branch of the National Cancer Institute, NIH, in Bethesda, MD, Dr Dudley investigated tumor rejection tumor rejection antigens, T cell specificity and function, and methods for the generation and administration to patients of T cell therapies. His work has resulted in more than 100 peer-reviewed publications, and he is co-author on numerous seminal papers including early tumor-infiltrating lymphocytes studies demonstrating that adoptive T-cell transfer has tumor eradicating potential. Dr. Dudley earned a Ph.D. in Biological Sciences at Stanford University, and had post- doctoral fellowships at The University of Pennsylvania in Philadelphia, PA and at the Jackson Laboratory in Bar Harbor, ME.
Parvez Ahammad joined BlackThorn Therapeutics as their Head of Data Science in November 2017. He has built teams and lead several successful applied machine learning initiatives in his career - most recently in web application delivery, web application security, and computational neuroscience. His recent work helped create two flagship product technologies (SmartVision and Helios) at Instart Logic, lead to Perceptual Speed Index (now part of Google Chrome Lighthouse), and won 2017 ACM-SigComm Internet-QoE best paper award.
Before moving to the industrial sector, Parvez worked at Howard Hughes Medical Institute's Janelia Research Campus, and UC-Berkeley. Parvez holds a PhD in electrical engineering and computer sciences from UC-Berkeley, with an emphasis in computer vision and machine learning. When he is not busy designing algorithms to mimic human perception, he enjoys being a dad to his two young kids and perfecting new ways to make them laugh.
John Cumbers has a strong background in the synthetic biology industry as founder and CEO of SynBioBeta, a global activity hub and community of entrepreneurs, thought-leaders, and investors. John is an active investor through the DCVC SynBioBeta Fund and his synthetic biology syndicate on AngelList. He is also the co-author of the forthcoming book “What’s Your Bio Strategy?”, a guide for any business wanting to understand the impact that biotechnology will have on their industry.
John has earned several degrees, including a Ph.D. in molecular biology from Brown University as well as a masters degree in bioinformatics from the University of Edinburgh in Scotland and an undergraduate degree in computer science from the University of Hull in England. John is passionate about education and on the use and adoption of biological technologies. He has received multiple awards and grants from NASA and the National Academy of Sciences for his work in the field.
John has been involved in multiple start-ups such as those producing food for space, microbes to extract lunar and martian resources, and hoverboards! He worked at NASA for seven years on the issues of resource utilization, extremophiles, and sustainable technologies. He was instrumental in starting NASA’s program in synthetic biology and most recently, the lead for planetary sustainability at the NASA Space Portal.
A super connector, community builder, and consultant, John has devoted himself to helping those around him connect into the synthetic biology ecosystem and gain the resources that they need to break through scientific boundaries and see their innovations applied in the real world.
Joseph is currently the Associate Director of IT & Informatics at Tango Therapeutics, Inc. At Tango, Joseph is responsible for the development and implementation of IT and informatics strategies across the company’s functional areas. Prior to this role, Joseph was the Manager of Research Informatics Applications at Sage Therapeutics, Inc. where he owned the planning, implementation, and maintenance of all informatics systems across the research portfolio. Before joining Sage,
Joseph spent several years at Vertex Pharmaceuticals, Inc. first as a medicinal chemist and then as an applications analyst in the Research Computing group. Joe has experience building home-grown research applications as well as designing and executing the integration of commercially available systems.
Joseph received his B.S. in chemistry from Boston College and his M.S. in Organic Chemistry from Yale University.
Sven Karlsson is the co-founder and president of Platelet BioGenesis. He has more than a decade experience in business development and financial analysis. Prior to co-founding Platelet BioGenesis he worked as a merger and acquisition principal at J.P. Morgan, an analyst at a hedge fund, and as a venture capital investor. He earned his M.B.A. from the Stern School of Business at New York University.
Jim Lillie is the Chief Scientific Officer at OvaScience. Since January, 2018 he's managed the scientific, research and technological operations of OvaScience. He helps set company research and scientific priorities so that they line up with the overall mission and goals of the organization and represent the scientific goals and interests of the company to shareholders. Dr. Lillie joined OvaScience from Sanofi Genzyme where he was Vice President, In Vitro Biology In this role, Dr. Lillie was responsible for developing a scientific strategy for creating a sustainable, high value portfolio in rare diseases. He established a strong pipeline of small molecule drugs and supported the U.S. Food and Drug Administration’s approval of Eliglustat and acceptance of two investigational new drug applications. Previously, he was Senior Director, In Vitro Biology at Sanofi Genzyme and, before that, he held roles of increasing responsibility at Millennium Pharmaceuticals, Inc. Earlier, he worked as Senior Director, Biology at Scriptgen Pharmaceuticals, and as co-founder at AMIRA, which was later sold to Repligen Corporation. Dr. Lillie holds a Ph.D. in Biochemistry and Molecular Biology from Harvard University and B.A. in German Literature from Wesleyan University.
Karina Chmielewski joined Third Rock in 2017 as senior director, platform operations to focus on the development, implementation, and refinement of technology roadmaps for companies across the firm’s portfolio.
Since 2015, Karina has served as a consultant to Third Rock, guiding companies on the identification and integration of drug discovery and development technology platforms. She led the informatics platform builds at Relay Therapeutics, Goldfinch Bio, and Tango Therapeutics and continues to work with our emerging companies in this capacity. Karina also served as a founding leader of the informatics team at Agios Pharmaceuticals where she led the development of the metabolomics platform, and TransForm Pharmaceuticals, where she led the development of technology platforms focused on data management, analytics, and automation. Karina holds a B.A and M.S. in Chemistry from Boston University, as well as an M.S. in Computer Science from Boston University.
Karina is a huge endurance sports enthusiast; she has completed a 140.6 mile IRONMAN race, is a 3-time Boston Marathon finisher, and a masters swimming world championship participant.
Bill Martin, Ph.D., serves as BlackThorn Therapeutics’ chief scientific officer and was a founding member of the company’s management team. Prior to joining BlackThorn, Bill was an executive director at Theravance Biopharma, where he led the company’s research portfolio planning initiative, was a member of the strategic partnership team and a project team leader for an advanced clinical-stage asset. Bill began his career at Merck where he contributed to the strategic direction of Merck’s Neuroscience franchise and chaired multiple CNS development teams. Bill has helped advance more than 10 new chemical entities into development. He is an author on more than 70 primary research and review articles and a former councilor of the Society for Neuroscience.
Dr. Mark Ashwell is Senior Vice President, Chemistry at Nimbus. He has worked in R&D in both biotech and pharma for more than 25 years, with experience advancing research portfolios across multiple target classes and therapeutic areas. Mark specializes in the fields of drug discovery research, technology utilization, portfolio creation and management, and business development. Before joining Nimbus, he was Principal Consultant at Ashwell Consulting Group, where he provided strategic counsel to biotech, pharma, academia, and R&D service industries in a number of areas including oncology, medicinal chemistry, structure-based drug discovery, intellectual property creation and atypical modes of target inhibition. Prior to this, Mark was Vice President, Head of Chemistry at ArQule Inc., where he built and managed a cross-functional team responsible for multiple research collaborations, which significantly contributed to the delivery of eight INDs into clinical development. Mark completed two postdoctoral research fellowships, worked as an NIH-funded World Health Organization consultant, and received his B.Sc. in Chemistry and his Ph.D. in Organic Chemistry from the University of Birmingham in the U.K. He has published over 30 peer-reviewed research papers and is listed as an inventor of 50 U.S.-granted patents and over 30 international filings.
Dr. Rebecca Carazza is Director of Research Informatics at Nimbus. She has worked in the biotech industry for 20 years originally as a research chemist then transitioned to Informatics. Rebecca’s specialties are in bridging the gap between researchers and software engineers to design and implement solutions to drive efficiency and simplicity. Before joining Nimbus, she was Senior Manager, Research Informatics at Amgen Inc. providing service to the Lead Identification and Lead Optimization functions. Prior to this, Rebecca was Associate Director, Informatics and Engineering at ArQule Inc. where she led cross functional teams to design and implement software and hardware solutions to support drug discovery programs. Rebecca received her Ph.D. in Chemistry from Massachusetts Institute of Technology and a B.S. in Chemistry from the University of Massachusetts, Amherst.
Micah is a Managing Partner with Founder Collective, a seed investor in Uber, BuzzFeed, Dia & Co, Cruise, Hotel Tonight and more. Before becoming a VC Micah started three companies; Sample6, a diagnostic/monitoring platform for bacteria in food/healthcare settings; Brontes Technologies, an intraoral 3-D scanner for dentists that replaced gooey, uncomfortable and inaccurate dental impressions, which sold to 3M for $95M; And his very first startup was Handshake.com, a consumer web company in 1999-2001 that was booking house cleaners and black cars long before it was a "thing."
Micah's first job was for one of Hollywood’s premier talent agencies, Endeavor, the subject of the TV series Entourage, as a mail clerk. Micah has a BS from Cornell, MBA from Harvard Business School and because of his experience at Endeavor, can fix any make/model of photocopier.
David Craford is an entrepreneurial leader with proven experience developing, launching and growing high-value life science tools, informatics, and molecular diagnostics businesses. He is the president and CEO at Cytobank - a SaaS platform for machine learning-based analysis of high-complexity life sciences data.
Molly is an associate with Flagship Pioneering, working as part of a team of entrepreneurial scientists to conceive, create, and grow first-in-class scientific ventures. Prior to joining Flagship, Molly lead the development of data strategy and computational capabilities at Kaleido Biosciences, a start-up focused on developing novel chemistries to target the microbiome. Having started her career in software engineering in tech, she is continually drawn to the unique challenges of data-driven solutions in biology and medicine.
Alec received his Bachelor of Science degree in Honours Biotechnology from the University of British Columbia where he started his first company, M Prep, focusing on pre-medical education. In 2014, Alec transitioned to Harvard Business School’s MBA program, spending one year at the MBA before leaving to pursue new startup ventures. He teamed up with co-founder Mardonn Chua to craft spirits and wine from their individual molecular components at Ava, where Alec has been CEO since 2016.
Ethan graduated as a Dean's Scholar with a Bachelor's Degree in Food Science from the University of Delaware. He has spent his career working with startups and established food companies focusing on quantifying our senses and specializes in product design and data application. A food lover at his core, the move to Ava opened up the depth of exploration of his favorite subjects - food, wine, and spirits- to a nearly unimaginable level.
Dr. Elizabeth Iorns is the Founder, President & CEO of Science Exchange; Chairman of Science Exchange Board of Directors; Co-Director of the Reproducibility Initiative; Board Director of the Drug, Chemical & Associated Technologies Association (DCAT); Advisory Board Member of Meta-Research Innovation Center at Stanford (METRICS); and a Part-time Partner at Y Combinator.
Elizabeth has a Ph.D. in Cancer Biology from the Institute of Cancer Research (UK) and, before launching Science Exchange, was an Assistant Professor at University of Miami’s Miller School of Medicine where she investigated breast cancer development and progression. Elizabeth has been featured in multiple media outlets and she regularly speaks at thought leadership events, such as the 2017 TechCrunch Disrupt, 2017 Society for Laboratory Automation and Screening annual meeting and the 2016 MassBio CRO/CMO Symposium.
Elizabeth has received a range of honors and recognition, including one of Goldman Sachs' '100 Most Intriguing Entrepreneurs'; finalist for Scrip's Executive of the Year Award; Kevin Abosch 'Women in Tech' portrait series; Nature Magazine’s 'Ten People Who Mattered'; ELLE's Women in Tech; University of Auckland's '40 Under 40 Alumni'; Stevie Awards Female Entrepreneur of the Year; University of London Chairman's Prize for Best Graduating PhD Student; the Kauffman Foundation Emerging Entrepreneur Award; and one of WIRED’s '50 Women Who Are Changing The World'.
Over the course of the last decade, first as a graduate student at Harvard University in the Department of Molecular and Cell Biology with PhD advisor Professor Stuart Schreiber and then as an independent postdoctoral fellow at the Lewis-Sigler Institute at Princeton University, Dr. Ethan Perlstein developed an approach to studying old drugs and discovering new drugs in model organisms called evolutionary pharmacology. Ethan is an author on 19 peer-reviewed scholarly publications, including the discovery of a novel mechanism of action for the antidepressant Zoloft based on studies in yeast cells.
Dana Vanderwall is Head IT Business Partner for Biology & Pre-Clinical Research at Bristol-Myers Squibb. Dana is responsible for the strategy to enable data flow, analytics, knowledge capture, and provide general laboratory informatics capabilities to the Biology, Pharmaceutical Candidate Optimization, Drug Safety Evaluation and Veterinary Sciences functions at BMS.
Dana is also currently Chair of the Allotrope Foundation Board of the Directors, was part of the original team that developed the concepts and strategy that led to the launch of Allotrope in 2012, and has continued to play a part in the leadership, strategy, outreach and operational functions of the Foundation. He has contributed to a number of projects within the Pistoia Alliance and is active in the Society for Lab Automation and Screening.
Prior to joining BMS Dana was at GlaxoSmithKline and Merck, and has traversed Computational Chemistry, Cheminformatics, Computational & Structural Biology, and Biochemistry. He received his B.S. in Biochemistry at the University of Wisconsin, where he worked in the lab of W.W. Cleland, and his Ph.D. in Biochemistry at University of Maryland in the Lab of John Kozarich.
Adam Regelmann is the COO and Co-founder of Quartzy. In 2011, Adam launched Quartzy to help accelerate the pace of scientific discovery by improving the way labs manage their supplies. Adam has conducted extensive research in chemistry, microbiology, and immunology. He is passionate about the company’s mission to enable discovery by providing tools to labs that help solve the inefficiencies that plague bench research.
Adam is board certified in internal medicine, completing his residency at Washington University in St. Louis. He holds an M.D. and Ph.D. in Medicine, Immunology and Molecular Genetics along with a B.A in Biochemistry from Columbia University.
Amrit Chaudhuri is the CEO and Co-founder of Mass Innovation Labs. Amrit is a successful serial entrepreneur who has turned his vision for an Accelerated Commercialization Platform for the hottest up-and-coming biotechs into one of the leading research spaces in the world. While studying Biomedical Engineering and Synthetic Chemistry at Boston University, Amrit spun out Advanced Peptides, a specialty contract research organization focused on peptide chemistry. As the founder and CEO, he grew the company to 100+ employees, with 2 products commercialized, and 3 pharma collaborations. From Advanced Peptides, Amrit founded Boston Synthetic, a chemistry based bio-informatics company which was founded in 2011 and acquired in 2013.
Josh Wurzer is the Co-Founder and President of SC Laboratories, an analytical laboratory specializing in regulatory compliance and quality control testing for the Cannabis industry. With facilities in California and Oregon, SC Labs was founded in 2010 and is a market leader in servicing the Cannabis industry. He also serves on the board of directors of Envirocann, an organization that provides compliance and quality certifications for Cannabis producers and manufacturers of Cannabis products.
Josh received his Bachelors degree in Chemistry from the University of Wisconsin Green Bay.
A.J. Kumar is the Chief Scientific Officer at Jana Care. Jana Care builds Aina, an affordable, point-of-care diagnostic device for chronic disease that connect to smartphones and tablets to pair with a digital coaching and management program, Habits. A.J. is responsible for the R&D of the company and leading the development of new tests for diabetes, heart failure, and chronic kidney disease. Prior to Jana Care, A.J. completed a PhD and postdoc at Harvard University where he developed a point-of-care test for sickle cell disease in the lab of Prof. George Whitesides.
Andrew Hessel is the CEO of Humane Genomics Inc. The company is creating a software-directed process that, given any cancer cell, can design and manufacture a customized medicine to kill it, in just a few days. The company is seed funded by Deloitte. Previously, he was a distinguished researcher at design software giant Autodesk and co-chair of Biotechnology and Bioinformatics at Singularity University.
Tom was born and raised in Chicago, where he currently calls home with his family. But he spends most of his time in Silicon Valley working with biotechs. He was a PhD student in Molecular Pharmacology, dropped out, and started HappiLabs to make lab management and shopping a happier experience.
Diego Rey is a Visiting Partner at Y Combinator. Prior to joining YC, Diego was the CTO/Head of Research for the clinical diagnostics startup GeneWEAVE, which he co-founded in 2010 while at Cornell and which was acquired by Roche in 2015. GeneWEAVE is focused in advancing clinical microbiology with diagnostic solutions that will enable hospitals and physicians around the world to prevent and treat drug-resistant infections. Diego was responsible for the company's overall technology strategy, creation of intellectual property, and scientific research & development.
John Keilty joined Decibel Therapeutics from Third Rock Ventures where he served as the general manager of platform operations, responsible for the development and implementation of technology roadmaps for companies across the portfolio. Prior to this role, John was the vice president of information technology and informatics at Infinity Pharmaceuticals where he owned information systems, software development, computational science, biostatistics, clinical data management and clinical informatics. Before joining Infinity in 2002, John was an early member of Millennium Pharmaceuticals where he held various roles of increasing responsibility, with broad ownership for the creation, management, implementation and transfer of many of the company’s core genomic technologies. Before Millennium, John worked in the Howard Hughes lab of Michael Green at the University of Massachusetts Medical Center, focusing on basic research in transcription and gene splicing.
John received his B.A. in biology from Clark University and his M.S. in bioinformatics from Brandeis University.
Kevin has over 15 years of experience in pharmaceutical development and managing partnerships throughout North America, Europe, and Asia. He has a proven track record on evaluating, attaining, and developing new technologies that improve the development cycle, he developed the financial and technical justifications for Vertex’s continuous processing system, which Vertex uses today. Kevin is currently at Trek Therapeutics, a virtual company with CMOs all over the world. Kevin is currently developing both an IOT and block chain strategy for Trek as well as building an interconnected virtual laboratory. Kevin received his PhD in Chemical Engineering and his MBA from the University of Alberta.
Kevin J. Bittorf, PhD, MBA, Co-Founder and Vice President CMC, In-Licensing and Legal (IP & Contracting), Trek Therapeutics